Key Highlights

  • 11.09% is the pre-market decline indicated for Q/C Technologies, Inc. (NASDAQ:QCLS) on November 17, 2026, with shares indicated at USD 0.2854 against a calculated prior close of USD 0.3210.
  • 8.19 million shares were outstanding in the latest published data, implying a calculated market Capitalization of about USD 2.34 million at the indicated pre-market price of USD 0.2854 per share.
  • 18.34 million USD was the trailing net loss, equal to USD 3.17 per share, in the latest published data for the company, which has pharmaceutical and computing technology segments.
  • 96.51% is the calculated decline from the 52-week high of USD 8.17 to the indicated price, with a 52-week low of USD 0.4201 now sitting above the indicated level for Q/C shares.

What Moved Q/C Technologies, Inc. (NASDAQ:QCLS) in Pre-Market Trading on November 17, 2026 (-USD 0.0356, -11.09%)

Q/C Technologies, Inc. (NASDAQ:QCLS) is indicated at USD 0.2854 in pre-market trading on Tuesday, November 17, 2026, a pre-market move of -11.09%. The calculated prior close is USD 0.3210 (price divided by 0.8891) and the calculated USD move is -USD 0.0356. With 8.19 million shares outstanding, the calculated market capitalization is about USD 2.34 million.

The Rationale: No Same-Day Catalyst Identified Amid an Optical Computing Pivot for Q/C Technologies, Inc. (NASDAQ:QCLS)

No company release or filing dated November 17, 2026 was identified in published coverage, so the move is not attributed to a specific event. As general context, the company relocated its headquarters to San Francisco on July 1, 2026, appointed Yossef Ehrlichman as Founding Manager of Photonic Integrated Circuit Development on August 4, 2026, and announced a research collaboration with Sandia National Laboratories on its optical processing unit work. It filed its second quarter 2026 report on August 12, 2026 and a USD 100 million mixed securities shelf registration on February 11, 2026.

Valuation, Liquidity and Risks for Q/C Technologies, Inc. (NASDAQ:QCLS)

Q/C Technologies is described as a clinical-stage pharmaceutical company with Pharmaceuticals and Computing Technology segments. Its drug candidates include Isomyosamine, aimed at immunometabolic and autoimmune conditions, and Supera-CBD, a synthetic cannabidiol analog, while recent news has centered on photonic and optical computing. The trailing net loss is USD 18.34 million, or USD 3.17 per share. Revenue, cash and Debt figures were not found. The 52-week range runs from USD 0.4201 to USD 8.17, and the indicated price is 32.06% below the low (calculated). With a calculated Market Value under USD 100 million, this is a nano-cap with elevated dilution risk given the USD 100 million shelf. As general context, Nasdaq expects a USD 1.00 minimum bid price, and no deficiency notice was identified in published coverage.

Where Things Stand

The indicated pre-market price of USD 0.2854 for Q/C Technologies, Inc. (NASDAQ:QCLS) is 11.09% below a calculated prior close of USD 0.3210 on November 17, 2026. The company has about 8.19 million shares, a calculated market value near USD 2.34 million and a trailing net loss of USD 18.34 million. Its July 1, 2026 move to San Francisco, the August 12, 2026 Quarterly Report and a USD 100 million shelf registered on February 11, 2026 frame the backdrop. No same-day catalyst was identified, so thin liquidity and sub-dollar Volatility are general context rather than established causes. Pre-market quotes are indicative until the 9:30 a.m. ET open.